MX2021003032A - Composicion medicinal que incluye un anticuerpo monoclonal o fragmento de union a antigeno y uso del mismo. - Google Patents
Composicion medicinal que incluye un anticuerpo monoclonal o fragmento de union a antigeno y uso del mismo.Info
- Publication number
- MX2021003032A MX2021003032A MX2021003032A MX2021003032A MX2021003032A MX 2021003032 A MX2021003032 A MX 2021003032A MX 2021003032 A MX2021003032 A MX 2021003032A MX 2021003032 A MX2021003032 A MX 2021003032A MX 2021003032 A MX2021003032 A MX 2021003032A
- Authority
- MX
- Mexico
- Prior art keywords
- ptx3
- fab fragment
- antibody
- monoclonal antibody
- composition containing
- Prior art date
Links
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 title abstract 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 title abstract 3
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 abstract 6
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 abstract 6
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 abstract 6
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un anticuerpo monoclonal o fragmento de unión a antígeno, a un uso del mismo; el anticuerpo monoclonal o fragmento de unión a antígeno puede inhibir o atenuar específicamente la unión de PTX3 y el receptor de PTX3, siendo aplicado de este modo en un kit y un método de detección PTX3, así como composiciones y usos de inhibición o atenuación de una enfermedad o un síndrome relacionado a la unión de PTX3 y el receptor de PTX3.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/105733 WO2019056991A1 (zh) | 2017-09-19 | 2018-09-14 | 单克隆抗体或其抗原结合片段及其用途 |
| PCT/CN2018/106144 WO2019057024A1 (zh) | 2017-09-19 | 2018-09-18 | 含单克隆抗体或其抗原结合片段的医药组成物及其用途 |
| US201962867244P | 2019-06-27 | 2019-06-27 | |
| PCT/CN2019/105824 WO2020052675A1 (zh) | 2018-09-14 | 2019-09-13 | 含单株抗体或其抗原结合片段的医药组合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003032A true MX2021003032A (es) | 2021-05-27 |
Family
ID=69777381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003032A MX2021003032A (es) | 2018-09-14 | 2019-09-13 | Composicion medicinal que incluye un anticuerpo monoclonal o fragmento de union a antigeno y uso del mismo. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220119507A1 (es) |
| EP (1) | EP3862363A4 (es) |
| JP (1) | JP2022500503A (es) |
| KR (1) | KR20210062036A (es) |
| CN (2) | CN112739714B (es) |
| AU (1) | AU2019337248A1 (es) |
| BR (1) | BR112021004586A2 (es) |
| CA (1) | CA3112678A1 (es) |
| MX (1) | MX2021003032A (es) |
| PH (1) | PH12021550529A1 (es) |
| SG (1) | SG11202102514QA (es) |
| TW (1) | TWI754171B (es) |
| WO (1) | WO2020052675A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1235392A (en) * | 1991-01-14 | 1992-08-17 | New York University | Cytokine-induced protein, tsg-14, dna coding therefor and uses thereof |
| ITMI20040858A1 (it) * | 2004-04-29 | 2004-07-29 | Farma Dev S R L | Anticorpi monoclonali ibridomi metodo migliorato per determinare la proteina ptx3 e kit per detta determinazione |
| US7955807B2 (en) * | 2005-11-11 | 2011-06-07 | The University Of Tokyo | Method of measuring PTX3 with high sensitivity |
| TWI528969B (zh) * | 2013-06-07 | 2016-04-11 | 國立成功大學 | 胺基酸序列用於製備抑制ｐｔｘ３治療鼻咽癌之醫藥組合物之用途 |
| TW201532611A (zh) * | 2014-02-26 | 2015-09-01 | Univ Nat Cheng Kung | 醫藥組成物用以製備治療癌症藥物之用途 |
| TWI531375B (zh) * | 2015-05-29 | 2016-05-01 | 國立成功大學 | 抑制癌細胞活性之短肽治療劑及含此之醫藥組成物 |
| CN106188244B (zh) * | 2015-05-29 | 2019-12-27 | 王育民 | 抑制癌细胞活性的短肽治疗剂及含有它的医药组合物 |
| WO2019056991A1 (zh) * | 2017-09-19 | 2019-03-28 | 臻崴生物科技有限公司 | 单克隆抗体或其抗原结合片段及其用途 |
-
2019
- 2019-09-12 TW TW108133090A patent/TWI754171B/zh active
- 2019-09-13 JP JP2021538885A patent/JP2022500503A/ja active Pending
- 2019-09-13 CN CN201980058876.2A patent/CN112739714B/zh active Active
- 2019-09-13 BR BR112021004586-4A patent/BR112021004586A2/pt unknown
- 2019-09-13 US US17/274,960 patent/US20220119507A1/en active Pending
- 2019-09-13 CN CN202311402782.7A patent/CN117417443A/zh active Pending
- 2019-09-13 SG SG11202102514QA patent/SG11202102514QA/en unknown
- 2019-09-13 CA CA3112678A patent/CA3112678A1/en active Pending
- 2019-09-13 EP EP19861063.6A patent/EP3862363A4/en active Pending
- 2019-09-13 AU AU2019337248A patent/AU2019337248A1/en not_active Abandoned
- 2019-09-13 MX MX2021003032A patent/MX2021003032A/es unknown
- 2019-09-13 WO PCT/CN2019/105824 patent/WO2020052675A1/zh unknown
- 2019-09-13 KR KR1020217010919A patent/KR20210062036A/ko active Search and Examination
-
2021
- 2021-03-11 PH PH12021550529A patent/PH12021550529A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022500503A (ja) | 2022-01-04 |
| PH12021550529A1 (en) | 2022-02-21 |
| KR20210062036A (ko) | 2021-05-28 |
| CA3112678A1 (en) | 2020-03-19 |
| AU2019337248A1 (en) | 2021-04-08 |
| EP3862363A4 (en) | 2022-06-08 |
| TWI754171B (zh) | 2022-02-01 |
| CN112739714B (zh) | 2023-11-14 |
| US20220119507A1 (en) | 2022-04-21 |
| CN112739714A (zh) | 2021-04-30 |
| CN117417443A (zh) | 2024-01-19 |
| BR112021004586A2 (pt) | 2021-05-25 |
| SG11202102514QA (en) | 2021-04-29 |
| WO2020052675A1 (zh) | 2020-03-19 |
| TW202023616A (zh) | 2020-07-01 |
| EP3862363A1 (en) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190983A1 (ru) | Новое антитело к с-kit | |
| BR112019005823A2 (pt) | tratamento para enxaqueca refratária | |
| BR112018067522A2 (pt) | anticorpos específicos para receptor de poliovírus humano (pvr) | |
| BR112015022123A8 (pt) | Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit | |
| ZA201700528B (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| EA201692192A1 (ru) | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ | |
| MX355268B (es) | Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos. | |
| NZ760841A (en) | Agonist antibodies that bind human cd137 and uses thereof | |
| BR112015022260A2 (pt) | anticorpo monoclonal, polinucleotídeo, composição farmacêutica, fragmento isolado de tau, uso de um anticorpo, método de triagem de um agente e ácido nucleico | |
| SG11202103670XA (en) | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex | |
| PE20170768A1 (es) | Anticuerpos de union a protofibrillas ab mejorados | |
| MX2020009037A (es) | Anticuerpos de b7-h4 y métodos para usarlos. | |
| CY1118046T1 (el) | Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου | |
| PH12019500342A1 (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
| PH12016501579A1 (en) | Novel anti-presepsin antibody | |
| PH12015501632A1 (en) | Humanized anti-hmgbi antibody or antigen-binding fragment thereof | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
| BR112019010331A2 (pt) | composição farmacêutica para evitar a dependência de opioides | |
| PH12021550529A1 (en) | Medicinal composition containing monoclonal antibody or antibody fab fragment thereof, and use thereof | |
| PH12018501674A1 (en) | Anti-citrullinated hla polypeptide antibodies and uses thereof | |
| MX2021012406A (es) | Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1. | |
| MX2022005718A (es) | Anticuerpos tmem219 y usos terapeuticos de los mismos. | |
| BR112018075901A2 (pt) | anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitro |